Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Circulation ; 148(16): 1271-1286, 2023 10 17.
Article in English | MEDLINE | ID: mdl-37732422

ABSTRACT

Advances in cancer therapeutics have led to dramatic improvements in survival, now inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities associated with specific cancer therapeutics adversely affect the outcomes of patients with cancer. Advances in cardiovascular imaging have solidified the critical role for robust methods for detecting, monitoring, and prognosticating cardiac risk among patients with cancer. However, decentralized evaluations have led to a lack of consensus on the optimal uses of imaging in contemporary cancer treatment (eg, immunotherapy, targeted, or biological therapy) settings. Similarly, available isolated preclinical and clinical studies have provided incomplete insights into the effectiveness of multiple modalities for cardiovascular imaging in cancer care. The aims of this scientific statement are to define the current state of evidence for cardiovascular imaging in the cancer treatment and survivorship settings and to propose novel methodological approaches to inform the optimal application of cardiovascular imaging in future clinical trials and registries. We also propose an evidence-based integrated approach to the use of cardiovascular imaging in routine clinical settings. This scientific statement summarizes and clarifies available evidence while providing guidance on the optimal uses of multimodality cardiovascular imaging in the era of emerging anticancer therapies.


Subject(s)
Cardiovascular Diseases , Neoplasms , United States , Humans , American Heart Association , Neoplasms/diagnostic imaging , Neoplasms/therapy , Medical Oncology , Multimodal Imaging/methods , Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/therapy
2.
Cancer ; 127(24): 4646-4655, 2021 12 15.
Article in English | MEDLINE | ID: mdl-34411296

ABSTRACT

BACKGROUND: Limited data exist regarding left ventricular remodeling patterns observed in adult survivors of childhood cancer after therapy. METHODS: Among 1190 adult survivors diagnosed with childhood cancer (median age at diagnosis, 9 years [interquartile range (IQR), 3.8-14.4 years]; age at evaluation, 35.6 years [IQR, 29.5-42.8 years]), treatment exposures included anthracyclines (n = 346), chest radiotherapy (n = 174), both (n = 245), or neither (n = 425). Prospective echocardiographic assessment compared survivors with 449 noncancer controls classified according to left ventricle geometric patterns. Associations between left ventricle geometric patterns and decreased exercise tolerance were assessed. RESULTS: Overall, 28.2% of survivors (95% confidence interval [CI], 25.6%-30.8%) exhibited concentric remodeling, 2.4% (95% CI, 1.6%-3.5%) exhibited eccentric hypertrophy, and 1.1% (95% CI, 0.6%-1.9%) exhibited concentric hypertrophy. A greater proportion of survivors who received only chest radiotherapy (41%) had concentric remodeling compared with those who received only anthracyclines (24%), both (27%), or neither (27%; all P < .001), and all were greater than the proportions in noncancer controls (18%; all P < .05). Concentric remodeling was associated with radiation exposure, but not with anthracycline exposure, in multivariable models. Survivors who had concentric remodeling were more likely to have a maximal oxygen uptake peak <85% compared with those who had normal geometry (81.0% vs 66.3%; odds ratio, 1.75; 95% CI, 1.15-2.68). CONCLUSIONS: Chest radiation therapy, but not anthracycline therapy, increased the risk for concentric remodeling in survivors of childhood cancer. The presence of concentric remodeling was associated with increased exercise intolerance.


Subject(s)
Cancer Survivors , Neoplasms , Radiation Exposure , Adult , Anthracyclines/adverse effects , Child , Cohort Studies , Humans , Neoplasms/drug therapy , Neoplasms/radiotherapy , Prospective Studies , Survivors , Ventricular Remodeling
3.
Cancer ; 127(3): 458-466, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33108003

ABSTRACT

BACKGROUND: Survivors of childhood cancer exposed to cardiotoxic therapies are at significant cardiovascular risk. The utility of cardiac biomarkers for identifying the risk of future cardiomyopathy and mortality is unknown. METHODS: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) were assessed in 1213 adults 10 or more years from a childhood cancer diagnosis; 786 were exposed to anthracycline chemotherapy and/or chest-directed radiation therapy (RT). NT-proBNP values above age- and sex-specific 97.5th percentiles were considered abnormal. Generalized linear models estimated cross-sectional associations between abnormal NT-proBNP and anthracycline or chest RT doses as risk ratios with 95% confidence intervals (CIs). A Poisson distribution estimated rates and a Cox proportional hazards model estimated hazard ratios (HRs) for future cardiac events and death. RESULTS: At a median age of 35.5 years (interquartile range, 29.8-42.5 years), NT-proBNP and cTnT were abnormal in 22.5% and 0.4%, respectively. Exposure to chest RT and exposure to anthracycline chemotherapy were each associated with a dose-dependent increased risk for abnormal NT-proBNP (P for trend <.0001). Among exposed survivors with no history of Common Terminology Criteria for Adverse Events-graded cardiomyopathy and with normal systolic function, survivors with abnormal NT-proBNP had higher rates per 1000 person-years of cardiac mortality (2.93 vs 0.96; P < .0001) and future cardiomyopathy (32.10 vs 15.98; P < .0001) and an increased risk of future cardiomyopathy (HR, 2.28; 95% CI, 1.28-4.08) according to a multivariable assessment. CONCLUSIONS: Abnormal NT-proBNP values were prevalent and, among survivors who were exposed to cardiotoxic therapy but did not have a history of cardiomyopathy or current systolic dysfunction, identified those at increased risk for future cardiomyopathy. Further longitudinal studies are needed to confirm this novel finding.


Subject(s)
Cancer Survivors , Cardiomyopathies/diagnosis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Troponin T/blood , Adult , Biomarkers/blood , Cardiomyopathies/blood , Cardiomyopathies/mortality , Cardiotoxicity , Child , Cohort Studies , Female , Humans , Male , Proportional Hazards Models , Young Adult
4.
JAMA Oncol ; 6(8): 1194-1202, 2020 08 01.
Article in English | MEDLINE | ID: mdl-32584369

ABSTRACT

Importance: Exercise intolerance is associated with increased risk for morbidity and mortality in childhood cancer survivors. However, an association between exercise intolerance and psychosocial outcomes has not been fully explored. Objective: To examine the associations between exercise intolerance and emotional distress, attainment of social roles, and health-related quality of life in childhood cancer survivors. Design, Setting, and Participants: A cross-sectional study including 1041 adult survivors of childhood cancer and 286 community controls in the St Jude Lifetime Cohort was conducted at St Jude Children's Research Hospital. The study was performed from April 1, 2012, to March 15, 2020. Exposures: Exercise intolerance was defined as relative peak oxygen uptake less than 85% of age- and sex-estimated levels from maximal cardiopulmonary exercise testing. Main Outcomes and Measures: Emotional distress was measured with the 18-item Brief Symptom Inventory-18, which includes overall Global Severity Index and depression, anxiety, and somatization subscales. Participants with T scores greater than or equal to 63 were classified as having elevated levels of distress. Social attainment was evaluated using patient-reported educational, employment, and marital status. Health-related quality of life was examined with the Medical Outcomes Survey Short Form-36. Participants with T scores less than or equal to 40 were classified as reporting poor health-related quality of life. Results: Of the 1041 participants, 528 were women (50.7%). The prevalence of exercise intolerance among survivors (mean [SD] age, 35.5 [9.2] years) was higher than that among controls (age, 34.5 [10.0] years) (survivors: 634 [60.9%] vs controls: 75 [26.2%], P < .001). After adjusting for age at diagnosis and cardiopulmonary exercise testing, sex, race/ethnicity, smoking, physical activity, and exercise intolerance were associated with an increased risk for anxiety (prevalence rate ratio [PRR], 1.95; 95% CI, 1.20-3.16), somatization (PRR, 1.86; 95% CI, 1.23-2.80), and unemployment (PRR, 1.76; 95% CI, 1.23-2.52); an inverse association was noted with having a college degree (PRR, 0.67; 95% CI, 0.50-0.88). Exercise intolerance was associated with an increased the risk for scoring less than or equal to 40 on the physical component summary of the Medical Outcomes Survey Short Form-36 (PRR, 3.69; 95% CI, 2.34-5.84). These associations persisted when either cancer treatment exposures or chronic health conditions were added to the model. Conclusions and Relevance: The findings of this study suggest that exercise intolerance is independently associated with emotional distress, attainment of social roles, and health-related quality of life of long-term survivors of childhood cancer. The results also suggest that improving physiologic capacity may benefit general health and wellness, as well as emotional health, ability to participate in social roles, and health-related quality of life.


Subject(s)
Cancer Survivors/psychology , Exercise Tolerance , Psychological Distress , Quality of Life , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Role , Socioeconomic Factors , Young Adult
5.
J Clin Oncol ; 38(1): 29-42, 2020 01 01.
Article in English | MEDLINE | ID: mdl-31622133

ABSTRACT

PURPOSE: Exercise intolerance, associated with heart failure and death in general populations, is not well studied in survivors of childhood cancer. We examined prevalence of exercise intolerance in survivors exposed or not to cardiotoxic therapy, and associations among organ system function, exercise intolerance, and mortality. METHODS: Participants consisted of 1,041 people who had survived cancer ≥ 10 years (and had or did not have exposure to anthracyclines and/or chest-directed radiation) and 285 control subjects. Exercise intolerance was defined as peak oxygen uptake < 85% predicted from maximal cardiopulmonary exercise testing; organ functions were ascertained with imaging or clinical testing. Multivariable regression of the data was performed to compare exercise capacity between survivors exposed or unexposed to cardiotoxic therapy and control subjects, and to evaluate associations between treatment and organ function, and organ function and exercise intolerance. Propensity score methods in time-to-event analyses evaluated associations between exercise intolerance and mortality. RESULTS: Survivors (mean age ± standard deviation [SD], 35.6 ± 8.8 years) had lower mean (± SD) peak oxygen uptake (exposed: 25.74 ± 8.36 mL/kg/min; unexposed: 26.82 ± 8.36 mL/kg/min) than did control subjects (32.69 ± 7.75 mL/kg/min; P for all < .001). Exercise intolerance was present in 63.8% (95% CI, 62.0% to 65.8%) of exposed survivors, 55.7% (95% CI, 53.2% to 58.2%) of unexposed survivors, and 26.3% (95% CI, 24.0% to 28.3%) of control subjects, and was associated with mortality (hazard ratio, 3.9; 95% CI, 1.09 to 14.14). Global longitudinal strain (odds ratio [OR], 1.71; 95% CI, 1.11 to 2.63), chronotropic incompetence (OR, 3.58; 95% CI, 1.75 to 7.31); forced expiratory volume in 1 second < 80% (OR, 2.59; 95% CI, 1.65 to 4.09), and 1 SD decrease in quadriceps strength (OR, 1.49; 95% CI, 1.23 to 1.82) were associated with exercise intolerance. Ejection fraction < 53% was not associated with exercise intolerance. CONCLUSION: Exercise intolerance is prevalent among childhood cancer survivors and associated with all-cause mortality. Treatment-related cardiac (detected by global longitudinal strain), autonomic, pulmonary, and muscular impairments increased risk. Survivors with impairments may require referral to trained specialists to learn to accommodate specific deficits when engaging in exercise.


Subject(s)
Cancer Survivors/statistics & numerical data , Exercise Tolerance/physiology , Multiple Organ Failure/mortality , Multiple Organ Failure/physiopathology , Neoplasms/mortality , Neoplasms/physiopathology , Adult , Anthracyclines/administration & dosage , Anthracyclines/adverse effects , Exercise Test , Female , Heart Diseases/epidemiology , Heart Diseases/mortality , Heart Diseases/physiopathology , Humans , Male , Multiple Organ Failure/epidemiology , Neoplasms/drug therapy , Neoplasms/epidemiology , Oxygen Consumption/physiology , Randomized Controlled Trials as Topic
6.
J Am Soc Echocardiogr ; 26(9): 1013-32, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23998694

ABSTRACT

Cardiac toxicity is one of the most concerning side effects of anti-cancer therapy. The gain in life expectancy obtained with anti-cancer therapy can be compromised by increased morbidity and mortality associated with its cardiac complications. While radiosensitivity of the heart was initially recognized only in the early 1970s, the heart is regarded in the current era as one of the most critical dose-limiting organs in radiotherapy. Several clinical studies have identified adverse clinical consequences of radiation-induced heart disease (RIHD) on the outcome of long-term cancer survivors. A comprehensive review of potential cardiac complications related to radiotherapy is warranted. An evidence-based review of several imaging approaches used to detect, evaluate, and monitor RIHD is discussed. Recommendations for the early identification and monitoring of cardiovascular complications of radiotherapy by cardiac imaging are also proposed.


Subject(s)
Echocardiography/standards , Heart/radiation effects , Multimodal Imaging/standards , Neoplasms/radiotherapy , Radiation Injuries/diagnosis , Radiation Injuries/therapy , Adult , Dose-Response Relationship, Radiation , Echocardiography/methods , Humans , Middle Aged , Multimodal Imaging/methods , Radiotherapy, Adjuvant/adverse effects , Risk
7.
Eur Heart J Cardiovasc Imaging ; 14(8): 721-40, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23847385

ABSTRACT

Cardiac toxicity is one of the most concerning side effects of anti-cancer therapy. The gain in life expectancy obtained with anti-cancer therapy can be compromised by increased morbidity and mortality associated with its cardiac complications. While radiosensitivity of the heart was initially recognized only in the early 1970s, the heart is regarded in the current era as one of the most critical dose-limiting organs in radiotherapy. Several clinical studies have identified adverse clinical consequences of radiation-induced heart disease (RIHD) on the outcome of long-term cancer survivors. A comprehensive review of potential cardiac complications related to radiotherapy is warranted. An evidence-based review of several imaging approaches used to detect, evaluate, and monitor RIHD is discussed. Recommendations for the early identification and monitoring of cardiovascular complications of radiotherapy by cardiac imaging are also proposed.


Subject(s)
Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/etiology , Heart/radiation effects , Multimodal Imaging/standards , Neoplasms/radiotherapy , Radiation Injuries/diagnosis , Radiation Injuries/etiology , Radiotherapy/adverse effects , Adult , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/therapy , Consensus , Dose-Response Relationship, Radiation , Europe , Humans , Radiation Injuries/physiopathology , Radiation Injuries/therapy , Risk , United States
10.
J Am Soc Echocardiogr ; 25(12): 1309-18, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23102836

ABSTRACT

BACKGROUND: Longitudinal strain (LS) imaging is an important tool for the quantification of left ventricular function and deformation, but its assessment is challenging in the presence of echocardiographic contrast agents (CAs). The aim of this study was to test the hypothesis that destruction of microbubbles using high mechanical index (MI) could allow the measurement of LS. METHODS: LS was measured using speckle strain (speckle-tracking LS [STLS]) and Velocity Vector Imaging (VVI) before and after CA administration in 30 consecutive patients. Low MI was used for left ventricular opacification and three-dimensional high MI for microbubble destruction. Four different settings were tested over 60 sec: (1) baseline LS without contrast, (2) LS after CA administration with low MI (0.3), (3) LS after CA administration with high MI (0.9), and (4) LS after microbubble destruction with high MI and three-dimensional imaging. RESULTS: Baseline feasibility of LS assessment (99.3% and 98.2% with STLS and VVI, respectively) was reduced after CA administration using STLS at low (69%, P < .0001) and high (95.4%, P = .0002) MI as well as with VVI (93.8%, P = .004, and 84.7%, P < .0001, respectively). STLS assessment was feasible with high MI after microbubble destruction (1.7% of uninterpretable segments vs 0.7%, P = .26) but not using VVI (7.2% vs 1.8%, P < .001). Regardless of which microbubbles or image settings were used, VVI was associated with significant variability and overestimation of global LS (for low MI, +4.7%, P < .01; for high MI, +3.3%, P < .001; for high MI after microbubble destruction, +1.3%, P = .04). CONCLUSIONS: LS assessment is most feasible without contrast. If a CA is necessary, the calculation of LS is feasible using the speckle-tracking method, if three-dimensional imaging is used as a tool for microbubble destruction 1 min after CA administration.


Subject(s)
Echocardiography/methods , Elasticity Imaging Techniques/methods , Fluorocarbons , Heart Ventricles/diagnostic imaging , Heart Ventricles/physiopathology , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/physiopathology , Albumins/drug effects , Elastic Modulus , Feasibility Studies , Female , Humans , Male , Microbubbles , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
11.
Rev. esp. cardiol. (Ed. impr.) ; 64(5): 409-415, mayo 2011. ilus, tab
Article in Spanish | IBECS | ID: ibc-123502

ABSTRACT

Las mejoras que se han producido en la detección y el tratamiento del cáncer han dado origen a una nueva cohorte de pacientes que alcanzan una supervivencia suficiente para que puedan aparecer complicaciones cardiacas derivadas del tratamiento del cáncer. La ecografía tridimensional ha sido validada como la modalidad ecográfica que aporta mayor exactitud al cálculo de la fracción de eyección, en comparación con la resonancia magnética, que es el patrón de referencia actual a este respecto, y ello hace que sea el método de elección para la evaluación inicial y el seguimiento de los pacientes tratados con quimioterapia.Si no se dispone de ecocardiografía tridimensional o si la calidad de las imágenes es insuficiente, el uso de contraste ecográfico puede ser útil para definir el límite endocárdico e identificar el vértice cardiaco verdadero, con lo que se mejora la capacidad del evaluador para calcular con exactitud los volúmenes y la fracción de eyección.El strain bidimensional parece prometedor como instrumento para identificar anomalías en la mecánica miocárdica en una fase muy temprana de la cardiotoxicidad y permite predecir una posterior disfunción sistólica manifiesta. Este parámetro puede ser útil en la detección de los pacientes tratados con quimioterapia que pueden obtener beneficio con el empleo de otra alternativa terapéutica, con lo que se reduciría la incidencia de la cardiotoxicidad y la morbimortalidad asociada a ella (AU)


The improvements in cancer detection and therapy have created a new cohort of patients who will experience sufficient survival to develop the cardiac complications of the cancer therapy. Three-dimensional echocardiography has been validated as the ultrasound modality with the best accuracy for the calculation of ejection fraction when compared to magnetic resonance imaging, the current gold standard, making it the tool of choice, when available, for the initial evaluation and follow up of the patient receiving chemotherapy.If three-dimensional echocardiography is not available, or if the quality of the images is inadequate, the use of ultrasound contrast can be useful for the definition of the endocardial border and identification of the true apex of the heart, enhancing the ability of the interpreter to accurately calculate volumes and ejection fraction.Two-dimensional strain appears promising as a tool to identify abnormalities in myocardial mechanics very early on during cardiotoxicity, allowing the prediction of later overt systolic dysfunction. This parameter may be useful in the detection of chemotherapy treated patients who could benefit from alternate therapies, thereby decreasing the incidence of cardiotoxicity and its associated morbidity and mortality (AU)


Subject(s)
Humans , Cardiotoxins/adverse effects , Antineoplastic Agents/adverse effects , Cardiovascular Diseases/chemically induced , Anthracyclines/adverse effects , Breast Neoplasms/drug therapy , Antibodies, Monoclonal, Humanized/adverse effects , Radionuclide Ventriculography/methods , Echocardiography, Three-Dimensional/methods
12.
Rev Esp Cardiol ; 64(5): 409-15, 2011 May.
Article in Spanish | MEDLINE | ID: mdl-21492985

ABSTRACT

The improvements in cancer detection and therapy have created a new cohort of patients who will experience sufficient survival to develop the cardiac complications of the cancer therapy. Three-dimensional echocardiography has been validated as the ultrasound modality with the best accuracy for the calculation of ejection fraction when compared to magnetic resonance imaging, the current gold standard, making it the tool of choice, when available, for the initial evaluation and follow up of the patient receiving chemotherapy. If three-dimensional echocardiography is not available, or if the quality of the images is inadequate, the use of ultrasound contrast can be useful for the definition of the endocardial border and identification of the true apex of the heart, enhancing the ability of the interpreter to accurately calculate volumes and ejection fraction. Two-dimensional strain appears promising as a tool to identify abnormalities in myocardial mechanics very early on during cardiotoxicity, allowing the prediction of later overt systolic dysfunction. This parameter may be useful in the detection of chemotherapy treated patients who could benefit from alternate therapies, thereby decreasing the incidence of cardiotoxicity and its associated morbidity and mortality.


Subject(s)
Antineoplastic Agents/adverse effects , Heart Diseases/chemically induced , Neoplasms/complications , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/toxicity , Heart Diseases/diagnosis , Heart Diseases/diagnostic imaging , Humans , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...